Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes. Issue 12 (1st July 2013)
- Record Type:
- Journal Article
- Title:
- Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes. Issue 12 (1st July 2013)
- Main Title:
- Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes
- Authors:
- Chaplin, Steve
Wilding, John - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Dapagliflozin (Forxiga) is the first SGLT2 inhibitor licensed for the treatment of type 2 diabetes. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Professor John Wilding discusses its potential role in treatment.</p> </abstract>
- Is Part Of:
- Prescriber. Volume 24:Issue 12(2013:Jun.)
- Journal:
- Prescriber
- Issue:
- Volume 24:Issue 12(2013:Jun.)
- Issue Display:
- Volume 24, Issue 12 (2013)
- Year:
- 2013
- Volume:
- 24
- Issue:
- 12
- Issue Sort Value:
- 2013-0024-0012-0000
- Page Start:
- 13
- Page End:
- 16
- Publication Date:
- 2013-07-01
- Subjects:
- Chemotherapy -- Periodicals
Drugs -- Prescribing -- Periodicals
615.1 - Journal URLs:
- http://www.prescriber.co.uk/view/0/index.html ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/psb.1076 ↗
- Languages:
- English
- ISSNs:
- 0959-6682
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6609.700100
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3448.xml